According to the latest announcement released by AIM Vaccine on March the 8th, the company plans to issue non-publicly traded RMB ordinary shares (i.e. domestic shares and/or non-publicly traded foreign shares) based on specific authorization. The funds raised will be used for constructing new production facilities for bivalent EV71-CA16 HFMD vaccines, developing COVID-19 variant mRNA vaccines (including but not limited to monovalent and multivalent vaccines targeting Omicron BA.5) and multivalent pneumococcal conjugate vaccines in the pipeline, supplementing operational capital, and for general corporate purposes.
According to market analysts, the domestic shares issued by AIM Vaccine in this targeted offering can only exit through A-shares in the future, indicating a clear sign of the company's intentions for an A-share listing.

AIM Vaccine announced that two candidates of COVID-19 mRNA vaccine were approved for clinical trials in Pakistan. One targeting SARS-nCoV-2 mutant is approved for Phase I clinical trial, while the other targeting original COVID-19 virus is approved for Phase III clinical trial of sequential booster vaccination.

The domestic vaccine leader, AIM Vaccine, released a morning notice that its candidate of EV71-CA16 bivalent HFMD vaccine (human diploid cell) recently obtained clinical approval from CDE.

On October 5th, AIM vaccine closed its global sale of shares. A total of 9.714 million H shares were sold globally, with 10% in Hong Kong and 90% abroad including an additional 15% over-allotment option. The offering price was HKD 16.16 per share, with a minimum subscription of 200 shares per lot. AIM Vaccine received massive subscriptions from investors worldwide.
At 9pm on October 6th (Hong Kong time), AIM Vaccine's H shares will be traded on HKSE.

Several domestic COVID-19 mRNA vaccine candidates had entered the clinical stage in the first half of this year. The company utilized the COVID-19 pipeline to quickly establish an mRNA vaccine development and production platform.
Recently, AIM Vaccine released Phase Ⅱ clinical trial data of its self-developed COVID-19 mRNA vaccine, LVRNA009, showing good cellular immune responses and safety.
Notably, this LVRNA009 vaccine also proved effective on Omicron variant according to independent third-party testing results.

AIM Vacin, a wholly-owned subsidiary of AIM Vaccine, obtained the approval from the National Medical Products Administration yesterday (December 1) for carrying out clinical trials of ACYW135 Meningococcus Conjugate Vaccine (MCV4).